Abstract:Background and purpose Recently, the pathogenic and intermediate GGC repeat expansion in NOTCH2NLC was detected in Parkinson's disease (PD). However, detailed clinical, neuroimaging, and pathological information of clinically diagnosed PD patients with pathogenic GGC repeat expansion in NOTCH2NLC remains scarce. Thus, we aimed to elucidate the clinical, neuroimaging, and pathological characteristics of PD patients carrying the pathogenic GGC repeat expansion in NOTCH2NLC. Methods The NOTCH2NLC GGC repeat expansion was screened in 941 sporadic PD patients and 244 unrelated probands. Comprehensive assessments were performed in three PD patients with pathogenic GGC repeat expansion in NOTCH2NLC. The repeat expansion length was estimated using CRISPR/Cas9-based targeted long-read sequencing. Results The three patients (two PD patients from Family 1 and one sporadic PD) carrying the pathogenic NOTCH2NLC expansion were reconfirmed with a diagnosis of clinically established PD. Although they lacked the typical neuronal intranuclear inclusion disease (NIID) magnetic resonance imaging (MRI) feature, the typical PD pattern of striatal dopamine transporter loss was detected. Notably, all three patients presented with systemic areflexia, and other secondary causes of polyneuropathy were excluded. Skin biopsy showed intranuclear inclusions and an absence of phosphorylated alpha-synuclein deposition in the skin nerve fibers of all three patients. Conclusions Although these clinically diagnosed PD patients with pathogenic GGC repeat expansion in NOTCH2NLC were hardly distinguishable from idiopathic PD based on clinical course and neuroimaging features, the pathological findings indicated that their phenotype was a PD phenocopy of NIID. Systemic areflexia may be an important and unique clinical clue suggesting further genetic testing and skin biopsy examination to confirm the diagnosis of NIID in patients presenting with a PD phenocopy.

High expression of nicotinamide N-methyltransferase in patients with idiopathic Parkinson's disease

Gene Expression Profiling of MPP+-treated MN9D Cells: A Mechanism of Toxicity Study

The role of NOTCH2NLC in Parkinson's disease: A clinical, neuroimaging, and pathological study

Abnormal DNA Methylation in Substantia Nigra Region of MPTP-induced Mouse Model of Parkinson's Disease

Reduced Nicotinamide Adenine Dinucleotide Phosphate Inhibits MPTP-Induced Neuroinflammation and Neurotoxicity

Nicotinamide riboside first alleviates symptoms but later downregulates dopamine metabolism in proteasome inhibition mouse model of Parkinson's disease

Mitochondrial complex I deficiency stratifies idiopathic Parkinson’s disease

Genetic Impacts on Nigral Iron Deposition in Parkinson's Disease: A Preliminary Quantitative Susceptibility Mapping Study.

Ablation of NAMPT in Dopaminergic Neurons Leads to Neurodegeneration and Induces Parkinson’s Disease in Mouse

Omics data integration suggests a potential idiopathic Parkinson's disease signature

NAMPT deficiency triggers dopaminergic neurodegeneration in the substantia nigra of mouse

[Protective Effect of Nicotinamide in a Mouse Parkinson's Disease Model].

Nicotinamide Mononucleotide Improves Energy Activity and Survival Rate in an in Vitro Model of Parkinson's Disease.

The Clinical Characteristics of Neuronal Intranuclear Inclusion Disease and Its Relation with Inflammation

Ablation of NAMPT in dopaminergic neurons leads to neurodegeneration and induces Parkinson's disease in mouse

Niacin, an innovative protein kinase-C-dependent endoplasmic reticulum stress reticence in murine Parkinson's disease

Inhibition of neuronal mitochondrial complex I or lysosomal glucocerebrosidase is associated with increased dopamine and serotonin turnover

High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson's disease

1.009 NIGRAL IRON DEPOSITION OCCURS ACROSS MOTOR PHENOTYPIC EXPRESSIONS OF PARKINSON'S DISEASE

Impact of potential biomarkers, SNRPE, COX7C, and RPS27, on idiopathic Parkinson's disease